8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Day One Biopharmaceuticals is successfully transitioning into a commercial-stage entity, evidenced by revenue growth to $53.7 million in 2025Q4. While the company benefits from high orphan drug pricing power, investors should monitor the persistent operating m...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 5, 2026 | -$0.35-12.9% vs -$0.31 | — vs $54M |
Q1 2026 Feb 24, 2026 | -$0.20-17.6% vs -$0.17 | $54M+7.7% vs $50M |
Q4 2025 Nov 4, 2025 | -$0.19+31.8% vs -$0.28 | $40M+4.2% vs $38M |
Q3 2025 Aug 5, 2025 | -$0.29+17.1% vs -$0.35 | $34M-14.4% vs $40M |
Benchmark DAWN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Day One Biopharmaceuticals, Inc. (DAWN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -22.74% | — | |
| $11.04 | $980.07M | -3.47 | 25.24% | -384.3% | -207.18% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Day One Biopharmaceuticals, Inc. (DAWN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Day One Biopharmaceuticals, Inc. (DAWN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 23, 2026·SEC
Mar 6, 2026·SEC
Mar 2, 2026·SEC
Get notified when DAWN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Day One Biopharmaceuticals, Inc. (DAWN) stock FAQ — growth, dividends, profitability & financials explained
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in revenue for fiscal year 2025.
Day One Biopharmaceuticals, Inc. (DAWN) grew revenue by 20.6% over the past year. This is strong growth.
Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $107.3M for fiscal year 2025.
Day One Biopharmaceuticals, Inc. (DAWN) has a return on equity (ROE) of -22.7%. Negative ROE indicates the company is unprofitable.
Day One Biopharmaceuticals, Inc. (DAWN) had negative free cash flow of $107.6M in fiscal year 2025, likely due to heavy capital investments.